AllInBio

ALLInBio is a clinical-stage precision medicine biotechnology company developing targeted immunology approaches for chronic inflammatory and immune-mediated diseases. The company's core focus is developing a precision immunology platform that enables the identification and selection of genetically at-risk patient populations, allowing for earlier and more targeted treatment of conditions before disease progression occurs. ALLInBio is advancing multiple programs toward clinical development targeting drug-resistant inflammatory and fibrotic diseases, with a research emphasis on translational drug development. The company is based in Palo Alto, California, at the Alexandria Center for Life Science, and has built an interdisciplinary team spanning molecular biology, immunology, corporate development, and AI capabilities. ALLInBio has received backing from Longitude Capital and is developing AI tools to support its growing pipeline of programs targeting chronic inflammatory conditions. The company's approach aims to transform how chronic immune-mediated diseases are managed by shifting intervention earlier in the disease course through improved patient stratification.